AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The UK company buys IRDx for $1bn.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
